Foghorn Therapeutics Inc.
FHTX
Price:
$9.31
Market Cap:
$515.11M
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor...[Read more]
Industry
Biotechnology
IPO Date
2020-10-23
Stock Exchange
NASDAQ
Ticker
FHTX
The ROE as of September 2024 (TTM) for Foghorn Therapeutics Inc. (FHTX) is 140.34%
According to Foghorn Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is 140.34%. This represents a change of 131.65% compared to the average of 60.58% of the last 4 quarters.
Foghorn Therapeutics Inc. (FHTX) Historical ROE (quarterly & annually)
How has FHTX ROE performed in the past?
The mean historical ROE of Foghorn Therapeutics Inc. over the last ten years is -16184.95%. The current 140.34% ROE has changed -100.87% with respect to the historical average. Over the past ten years (40 quarters), FHTX's ROE was at its highest in in the March 2020 quarter at 977.72%. The ROE was at its lowest in in the December 2022 quarter at -30475.67%.
Average
-16184.95%
Median
5.49%
Minimum
-97208.70%
Maximum
127.51%
Foghorn Therapeutics Inc. (FHTX) ROE by Quarter and Year
Discovering the peaks and valleys of Foghorn Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 91.12%
Maximum Annual ROE = 127.51%
Minimum Annual Increase = -181.31%
Minimum Annual ROE = -97208.70%
| Year | ROE | Change |
|---|---|---|
| 2023 | 127.51% | -100.13% |
| 2022 | -97208.70% | 91.12% |
| 2021 | -106.56% | 123.24% |
| 2020 | -47.73% | -181.31% |
| 2019 | 58.70% | -12.46% |
Foghorn Therapeutics Inc. (FHTX) Average ROE
How has FHTX ROE performed in the past?
The current ROE of Foghorn Therapeutics Inc. (FHTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-32395.92%
5-year avg
-19435.36%
10-year avg
-16184.95%
Foghorn Therapeutics Inc. (FHTX) ROE vs. Peers
How is FHTX’s ROE compared to its peers?
Foghorn Therapeutics Inc.’s ROE is greater than C4 Therapeutics, Inc. (-44.60%), greater than Cyteir Therapeutics, Inc. (-23.13%), greater than Prelude Therapeutics Incorporated (-59.82%), greater than Rezolute, Inc. (-60.90%), greater than Shattuck Labs, Inc. (-68.65%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Kymera Therapeutics, Inc. (-28.88%), greater than Nurix Therapeutics, Inc. (-67.78%), greater than Molecular Partners AG (-33.08%), greater than MediciNova, Inc. (-13.37%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), less than Champions Oncology, Inc. (323.52%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Century Therapeutics, Inc. (-65.37%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than Cullinan Oncology, Inc. (-28.37%),
| Company | ROE | Market cap |
|---|---|---|
| -44.60% | $438.91M | |
| -23.13% | $108.71M | |
| -59.82% | $143.06M | |
| -60.90% | $285.34M | |
| -68.65% | $175.64M | |
| -70.40% | $345.53M | |
| -28.88% | $3.08B | |
| -67.78% | $1.64B | |
| -33.08% | $172.94M | |
| -13.37% | $89.26M | |
| -122.97% | $54.20M | |
| 323.52% | $69.90M | |
| -21.96% | $78.05M | |
| -57.89% | $777.61M | |
| -65.37% | $136.82M | |
| -28.01% | $1.57B | |
| -42.61% | $576.83M | |
| -28.37% | $982.70M |
Build a custom stock screener for Foghorn Therapeutics Inc. (FHTX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Foghorn Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Foghorn Therapeutics Inc. (FHTX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Foghorn Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Foghorn Therapeutics Inc.'s ROE?
How is the ROE calculated for Foghorn Therapeutics Inc. (FHTX)?
What is the highest ROE for Foghorn Therapeutics Inc. (FHTX)?
What is the 3-year average ROE for Foghorn Therapeutics Inc. (FHTX)?
What is the 5-year average ROE for Foghorn Therapeutics Inc. (FHTX)?
How does the current ROE for Foghorn Therapeutics Inc. (FHTX) compare to its historical average?